{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:16:05Z","timestamp":1786637765508,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T00:00:00Z","timestamp":1585526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study aimed to evaluate treatment response, survival, safety profiles, and predictive factors to chimeric antigen receptor T cell (CAR-T) therapy in Chinese patients with relapsed or refractory B cell acute lymphoblast leukemia (R\/R B-ALL). 39R\/R B-ALL patients who underwent CAR-T therapy were included. Baseline data were collected from patients\u2019 electronic medical records. Patients\u2019 peripheral bloods, bone marrow aspirates, and biopsies were obtained for routine examination, and treatment response and survival profiles as well as adverse events were evaluated. The rates of complete remission (CR), CR with minimal residual disease (MRD) negative\/positive, and bridging to hematopoietic stem-cell transplantation (HSCT) were 92.3%, 76.9%, 15.4%, and 43.6%, respectively. The median event-free survival (EFS) was 11.6 months (95% confidence interval (CI): 4.0\u201319.2 months) and median overall survival (OS) was 14.0 months (95% CI: 10.9\u201317.1 months). Bridging to HSCT independently predicted better EFS and OS, while high bone marrow blasts level independently predicted worse EFS. The incidence of cytokine release syndrome (CRS) was 97.4%, and refractory disease as well as decreased white blood cell independently predicted higher risk of severe CRS. Other common adverse events included hematologic toxicities (grade I: 5.1%, grade II: 7.7%, grade III: 17.9%, grade IV: 69.2%), neurotoxicity (28.2%), infection (38.5%), and admission for intensive care unit (10.3%). In conclusion, CAR-T therapy presents with promising treatment response, survival and safety profiles, and higher disease burden predicts worse survival as well as increased risk of severe CRS in Chinese R\/R B-ALL patients.<\/jats:p>","DOI":"10.1038\/s41419-020-2388-1","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T11:03:05Z","timestamp":1585566185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients"],"prefix":"10.1038","volume":"11","author":[{"given":"Limin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenkun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyue","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-6200","authenticated-orcid":false,"given":"Jin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"key":"2388_CR1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/leu.2016.391","volume":"31","author":"I Aldoss","year":"2017","unstructured":"Aldoss, I. et al. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors. Leukemia 31, 777\u2013787 (2017).","journal-title":"Leukemia"},{"key":"2388_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1200\/JCO.2016.70.7836","volume":"35","author":"I Iacobucci","year":"2017","unstructured":"Iacobucci, I. & Mullighan, C. G. Genetic basis of acute lymphoblastic leukemia. J. Clin. Oncol. 35, 975\u2013983 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2388_CR3","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","volume":"381","author":"H Inaba","year":"2013","unstructured":"Inaba, H., Greaves, M. & Mullighan, C. G. Acute lymphoblastic leukaemia. Lancet 381, 1943\u20131955 (2013).","journal-title":"Lancet"},{"key":"2388_CR4","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","volume":"33","author":"CH Pui","year":"2015","unstructured":"Pui, C. H. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33, 2938\u20132948 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2388_CR5","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3109\/10428194.2013.856428","volume":"55","author":"S Dinner","year":"2014","unstructured":"Dinner, S., Lee, D. & Liedtke, M. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia. Leuk. Lymphoma 55, 1715\u20131724 (2014).","journal-title":"Leuk. Lymphoma"},{"key":"2388_CR6","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","volume":"109","author":"AK Fielding","year":"2007","unstructured":"Fielding, A. K. et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study. Blood 109, 944\u2013950 (2007).","journal-title":"Blood"},{"key":"2388_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11899-018-0457-7","volume":"13","author":"KW Phelan","year":"2018","unstructured":"Phelan, K. W. & Advani, A. S. Novel therapies in acute lymphoblastic leukemia. Curr. Hematol. Malig. Rep. 13, 289\u2013299 (2018).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2388_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-017-0070-9","volume":"6","author":"G Wei","year":"2017","unstructured":"Wei, G. et al. Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory\/relapsed acute lymphoblastic leukemia. Exp. Hematol. Oncol. 6, 10 (2017).","journal-title":"Exp. Hematol. Oncol."},{"key":"2388_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2388_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2018.00239","volume":"9","author":"C Tomuleasa","year":"2018","unstructured":"Tomuleasa, C. et al. Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia. Front. Immunol. 9, 239 (2018).","journal-title":"Front. Immunol."},{"key":"2388_CR11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.950","volume":"103","author":"CE Annesley","year":"2018","unstructured":"Annesley, C. E., Summers, C., Ceppi, F. & Gardner, R. A. The evolution and future of CAR T cells for B-cell acute lymphoblastic leukemia. Clin. Pharm. Ther. 103, 591\u2013598 (2018).","journal-title":"Clin. Pharm. Ther."},{"key":"2388_CR12","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13045-018-0593-5","volume":"11","author":"LN Zhang","year":"2018","unstructured":"Zhang, L. N., Song, Y. & Liu, D. CD19 CAR-T cell therapy for relapsed\/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies. J. Hematol. Oncol. 11, 41 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2388_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-018-0572-x","volume":"11","author":"J Weng","year":"2018","unstructured":"Weng, J. et al. A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia. J. Hematol. Oncol. 11, 25 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2388_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00277-018-3246-4","volume":"97","author":"G Wei","year":"2018","unstructured":"Wei, G. et al. CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory\/relapsed acute lymphoblastic leukemia: results of a case-controlled study. Ann. Hematol. 97, 781\u2013789 (2018).","journal-title":"Ann. Hematol."},{"key":"2388_CR15","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1017\/S147895151600095X","volume":"15","author":"V Prudent","year":"2017","unstructured":"Prudent, V. & Breitbart, W. S. Chimeric antigen receptor T-cell neuropsychiatric toxicity in acute lymphoblastic leukemia. Palliat. Support Care. 15, 499\u2013503 (2017).","journal-title":"Palliat. Support Care."},{"key":"2388_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/2040620715588916","volume":"6","author":"SK Tasian","year":"2015","unstructured":"Tasian, S. K. & Gardner, R. A. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther. Adv. Hematol. 6, 228\u2013241 (2015).","journal-title":"Ther. Adv. Hematol."},{"key":"2388_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13045-017-0535-7","volume":"10","author":"B Liu","year":"2017","unstructured":"Liu, B., Song, Y. & Liu, D. Clinical trials of CAR-T cells in China. J. Hematol. Oncol. 10, 166 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"2388_CR18","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1038\/leu.2012.26","volume":"26","author":"B Chen","year":"2012","unstructured":"Chen, B. et al. Newly diagnosed acute lymphoblastic leukemia in China (I): abnormal genetic patterns in 1346 childhood and adult cases and their comparison with the reports from Western countries. Leukemia 26, 1608\u20131616 (2012).","journal-title":"Leukemia"},{"key":"2388_CR19","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/leu.2012.23","volume":"26","author":"JQ Mi","year":"2012","unstructured":"Mi, J. Q. et al. Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases. Leukemia 26, 1507\u20131516 (2012).","journal-title":"Leukemia"},{"key":"2388_CR20","doi-asserted-by":"publisher","unstructured":"Wu, K. K., Lee, M. P., Lee, E. B. & Wu, J. J. Risk of herpes zoster with IL-17 inhibitor therapy for psoriasis and other inflammatory conditions. J. Dermatol. Treat. 1\u20137. https:\/\/doi.org\/10.1080\/09546634.2019.1597246 (2019). [Epub ahead of print].","DOI":"10.1080\/09546634.2019.1597246"},{"key":"2388_CR21","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","volume":"16","author":"KM Mahadeo","year":"2019","unstructured":"Mahadeo, K. M. et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol. 16, 45\u201363 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2388_CR22","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1200\/JCO.2009.27.2146","volume":"28","author":"ML Disis","year":"2010","unstructured":"Disis, M. L. Immune regulation of cancer. J. Clin. Oncol. 28, 4531\u20134538 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2388_CR23","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1056\/NEJMra072739","volume":"358","author":"OJ Finn","year":"2008","unstructured":"Finn, O. J. Cancer immunology. N. Engl. J. Med. 358, 2704\u20132715 (2008).","journal-title":"N. Engl. J. Med."},{"key":"2388_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/1078155217713363","volume":"24","author":"RK DasGupta","year":"2018","unstructured":"DasGupta, R. K., Marini, B. L., Rudoni, J. & Perissinotti, A. J. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. J. Oncol. Pharm. Pract. 24, 453\u2013467 (2018).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"2388_CR25","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1159\/000357163","volume":"40","author":"A Wieczorek","year":"2013","unstructured":"Wieczorek, A. & Uharek, L. Genetically modified T cells for the treatment of malignant disease. Transfus. Med. Hemother. 40, 388\u2013402 (2013).","journal-title":"Transfus. Med. Hemother."},{"key":"2388_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","volume":"65","author":"DM Barrett","year":"2014","unstructured":"Barrett, D. M. et al. Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 65, 333\u2013347 (2014).","journal-title":"Annu. Rev. Med."},{"key":"2388_CR27","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude, S. L., Teachey, D. T., Porter, D. L. & Grupp, S. A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125, 4017\u20134023 (2015).","journal-title":"Blood"},{"key":"2388_CR28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2388_CR29","doi-asserted-by":"publisher","first-page":"7028","DOI":"10.1200\/JCO.2017.35.15_suppl.7028","volume":"35","author":"L Xiao","year":"2017","unstructured":"Xiao, L. et al. Efficacy of anti-CD19 chimeric antigen receptor modified T (CAR-T) cell therapy in Chinese patients with relapsed\/refractory acute lymphocytic leukemia in a multicenter trial. J. Clin. Oncol. 35, 7028\u20137028 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2388_CR30","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"2388_CR31","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay, K. A. et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133, 1652\u20131663 (2019).","journal-title":"Blood"},{"key":"2388_CR32","doi-asserted-by":"crossref","unstructured":"Turtle, C. J., Hanafi, L.-A. & Berger, C. Addition of fludarabine to cyclophosphamide lymphodepletion improves in vivo expansion of CD19 chimeric antigen receptor-modified T cells and clinical outcome in adults with B cell acute lymphoblastic leukemia. Blood 126. https:\/\/www.researchgate.net\/publication\/308057143 (2015).","DOI":"10.1182\/blood.V126.23.3773.3773"},{"key":"2388_CR33","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood.2019001641","volume":"134","author":"KJ Curran","year":"2019","unstructured":"Curran, K. J. et al. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric\/young adult relapsed\/refractory B-ALL. Blood 134, 2361\u20132368 (2019).","journal-title":"Blood"},{"key":"2388_CR34","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295\u20132306 (2017).","journal-title":"Blood"},{"key":"2388_CR35","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2388_CR36","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey, D. T. et al. Identification of predictive biomarkers for caytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664\u2013679 (2016).","journal-title":"Cancer Discov."},{"key":"2388_CR37","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517\u2013528 (2015).","journal-title":"Lancet"},{"key":"2388_CR38","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8, 958\u2013971 (2018).","journal-title":"Cancer Discov."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2388-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2388-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:51:30Z","timestamp":1670251890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2388-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["2388"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-2388-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]},"assertion":[{"value":"20 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"207"}}